Cambridge Healthtech Institute's Fifth Annual

Antibody-Drug Conjugates

( 抗体药物复合物 )

Engineering for Clinical Success

2018年1月9日 - 10日


Cambridge Healthtech Institute's Antibody-Drug Conjugates conference reveals the engineering that has brought about today's ADC revolution, and examines how to design safe and effective therapeutics. Exploring options for selecting new targets and ensuring potency will be discussed, along with strategies for advancing ADCs to the clinic. A special focus on fighting cancer will be highlighted including tumor penetration. Analyzing ADCs to explore conjugation, stability, and payloads will also be addressed in this leading ADC event.

Preliminary Agenda

Advancing ADCs into the Clinic

Translational Safety of Antibody-Drug Conjugate: Opportunities to Mitigate Clinical Toxicities and Improve Therapeutic Index (TI) 

Rakesh Dixit, Ph.D., DABT, Vice President, R&D, and Global Head, Biologics Safety Assessment, Pathology and LAR, MedImmune, LLC (AstraZeneca Biologics)

Pre-Clinical Development of a Novel FLT3 Targeting Antibody-Drug Conjugate Employing Site-Specific Conjugate for the Treatment of Acute Myeloid Leukemia

Kendall Morrison, Ph.D., Director, Protein Technologies, Agensys, Inc. (an affiliate of Astellas Pharma)

Analyzing ADCs to Improve Properties

Exploring Higher Order Structure of ADCs with Biophysical Characterization Techniques

David Chiu, Ph.D., Scientist, Analytical Sciences, Seattle Genetics

Understanding Stability of ADCs Utilizing Deconjugation of Small Molecule Drugs

Colin Medley, Ph.D., Senior Scientist, Small Molecule Pharmaceutical Sciences, Genentech, Inc.

Engineering Next-Gen ADCs

HydraSpace Technology: A Versatile Ionic Spacer to Further Empower Glycan-Conjugated Antibody-Drug Conjugates

Floris Van Delft, Ph.D., Founder & CSO, SynAffix BV

Improving Production of ADCs

The Impact of Trisulfide Modification of Antibodies on the Properties of Antibody-Drug Conjugates Manufactured Using Thiol Chemistry

Thomas Ryll, Ph.D., Vice President, Process and Analytical Development, ImmunoGen, Inc.

Strategy to Advance ARX788 ADC Program from Development to Clinical Manufacturing

Yun Bai, Ph.D., Director, Process Development, Ambrx, Inc.

* 活动内容有可能不事先告知作更动及调整。